Abstract
The possibility of using technetium-99m(V) dimercaptosuccinic acid, Tc-99m DMSA, in the evaluation of uveal amelanotic melanoma was assessed in this study. Both planar and SPECT images clearly demonstrated the tumor. Following confirmation of our results by contemporaneous ultrasonography and MRI the patient was treated with Iodine-125 brachytherapy. In combination with other diagnostic tests, Tc-99m(V) DMSA scintigraphy may play a role in the detection of uveal melanoma and its possible systemic metastases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shields JA, Shields CL. Posterior uveal melanoma: Clinical and pathologic features.In: Shields JA, Shields CL, eds.; Intraocular tumors. A Text and Atlas, W.B. Saunders Company, Philadelphia, pp. 117–136, 1992.
Thomas CL, Krohmer JS, Stroraasli JP. Detection of intraocular tumors with radioactive phosphorus.Arch Ophtalmol 47: 276–286, 1952.
Beierwalters WH, Varma VM, Liebermann LM, Councell RE, Morales JO. Scintillation scanning of malignant melanomas with radioiodinated quinoline derivatives.J Lab Clin Med 72: 485–494, 1968.
Dencker L, Larsson B, Olander K, Ullberg S. A new melanoma seeker for possible clinical use: Selective accumulation of radiolabelled thiouracil.Br J Cancer 45: 95–104, 1982.
Holman BL, Wick MM, Kaplan ML, Hill TC, Lee RGL, Wu J, et al. The relationship of the eye uptake of N-isopropylp-(I-123)-iodoamphetamine to melanin production.J Nucl Med 25: 315–319, 1984.
Ono S, Fukunaga M, Otsuka N, Nagai K, Monta K, Furukawa T, et al. Visualization of ocular melanoma with N-isopropyl-p-(I-123)-iodoamphetamine.J Nucl Med 29: 1448–1450, 1988.
Van Langevelde A, Bakker CNM, Boer H, Ilmer TAM, Korver J, Kaspersen FM, et al. Potential radiopharmaceuticals for the detection ocular melanoma. Part II. Iodoquinoline derivatives and Ga-67 citrate.Eur J Nucl Med 12: 96–104, 1986.
Hirano T, Tomiyoshi K, Zhang J, Ishia T, Inoue T, Endo K, et al. Preparation and clinical evaluation of Tc-99m(V) DMSA for tumor imaging.Eur J Nucl Med 21: 82–85, 1994.
Bomanji J, Gardner A, Prasad J, Albert DM, Hungerford JL, Granowska M, et al. Characterization of ocular melanoma antibodies.Br J Ophthalmol 71: 647–650, 1987.
Bomanji J, Hungerford JL, Granowska M, Britton KE. Radioimmunoscintigraphy of ocular melanoma with Tc-99m labeled cutaneous melanoma antibody fragments.Br J Ophthalmol 71: 651–658, 1987.
Scheidhauer K, Markl A, Leisinger MG, Moser E, Scheiffarth OF, Reidel KG, et al. Immunoscintigraphy in intraocular malignant melanoma.Nucl Med Commun 9: 669–679, 1988.
Liewendahl K, Pyrhönen S. Radioimmunodetection and radioimmunotherapy of malignant melanoma.Acta Oncologica 32: 717–721, 1993.
Yokoyama A, Hata N, Horiuchi K, Masuda H, Saji H, Ohta H, et al. The design of Tc-99m(V) DMSA. Complex as a tumor imaging agent.Int J Nucl Med Biol 12: 273–279, 1985.
Ohta H, Endo K, Fujita T, Nakajima T, Sakahara H, Torizuka K, et al. Imaging of head and neck tumors with Tc-99m(V) DMSA: A new tumor seeking agent.Clin Nucl Med 10: 855–860, 1985.
Ohta H, Endo K, Fujita T, Nakajima T, Sakahara H, Torizuka K, et al. Imaging of soft tissue tumors with Tc-99m(V) DMSA: a new tumor seeking agent.Clin Nucl Med 9: 568–573, 1984.
Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu D, et al. A new imaging agent for medullary thyroid carcinoma of the thyroid.J Nucl Med 25: 323–325, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiratli, P.Ö., Kiratli, H., Ercan, M.T. et al. Visualization of uveal amelanotic melanoma with technetium-99m(V) dimercaptosuccinic acid. Ann Nucl Med 11, 147–149 (1997). https://doi.org/10.1007/BF03164824
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164824